Dengue Moment
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
For a country that has lived with dengue as a seasonal inevitability, the emergence of DengiAll, India’s indigenous single-shot dengue vaccine now in advanced trials in Delhi, is more than a scientific milestone.
The World Health Organization (WHO) has donated 2,160 doses of Ebola trial vaccine to Uganda to evaluate the efficacy of the vaccine in combating the virus which in the recent outbreak has killed a health worker in Kampala, the country's capital.
Indonesia is developing a new Tuberculosis (TB) vaccine to strengthen the fight against TB, which has claimed an average of 150,000 lives annually.
The landmark trial will evaluate the efficacy of India’s indigenous tetravalent dengue vaccine, DengiAll, developed by Panacea Biotec.
Specifically, the team compared the immune responses in people who were protected against CMV infection after receiving the older vaccine.
In the same period, 221 new fatalities were reported, which increased the death toll to 4,49,873.
The approval by Australia comes when the Bharat Biotech-manufactured Covid-19 vaccine is seeking an approval from the WHO for Covaxin.
The three dose DNA built vaccine has 66.6 per cent efficacy against Covid, says manufacturer Zydus Cadila.
"Children from six weeks of age group will receive the vaccines from immunisation centres from 3 November in the district, and at the time when they will get the first dose of polio, rotavirus, pentavalent vaccine and other routine vaccines,"
There was no system of providing pneumococcal vaccines to the toddlers from the state government so far. Parents procure the vaccines from chemists’ shops in open markets at around Rs 3,500 each for immunizations against pneumonia.
